Intravitreal Infliximab for the Treatment of Proliferative Vitreoretinopathy (FIXER)
- 31 May 2024
- journal article
- research article
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (11) , 1044-1051
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Inflammatory mediators of proliferative vitreoretinopathy: hypothesis and reviewInternational Ophthalmology, 2020
- Intravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Behçet Disease: A Pilot Study in 15 PatientsAmerican Journal of Ophthalmology, 2012
- TNF-α promotes human retinal pigment epithelial (RPE) cell migration by inducing matrix metallopeptidase 9 (MMP-9) expression through activation of Akt/mTORC1 signalingBiochemical and Biophysical Research Communications, 2012
- Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study GroupInternational Ophthalmology, 2012
- Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2009
- Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative VitreoretinopathyOphthalmology, 2008
- Retinal Redetachment after Silicone Oil Removal in Proliferative Vitreoretinopathy: A Prognostic Factor AnalysisAmerican Journal of Ophthalmology, 2008
- Randomized Controlled Trial of Combined 5-Fluorouracil and Low-Molecular-Weight Heparin in the Management of Unselected Rhegmatogenous Retinal Detachments Undergoing Primary VitrectomyOphthalmology, 2007
- Functional outcome and prognostic factors in 304 eyes managed by retinectomyGraefe's Archive for Clinical and Experimental Ophthalmology, 2006
- A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathyOphthalmology, 2004